We serve Chemical Name:1-prop-2-enylimidazolidine-2,4-dione CAS:3366-93-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-prop-2-enylimidazolidine-2,4-dione
CAS.NO:3366-93-6
Synonyms:1-ALLYLHYDANTOIN;1-allylhydantoin;1-allyl-imidazolidine-2,4-dione
Molecular Formula:C6H8N2O2
Molecular Weight:140.14000
HS Code:2933990090
Physical and Chemical Properties:
Melting point:97ºC
Boiling point:N/A
Density:1.188g/cm3
Index of Refraction:1.5
PSA:49.41000
Exact Mass:140.05900
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-ALLYLHYDANTOIN chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-allyl-imidazolidine-2,4-dione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-allylhydantoin Use and application,1-ALLYLHYDANTOIN technical grade,usp/ep/jp grade.
Related News: You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 1-prop-2-enylimidazolidine-2,4-dione manufacturer AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 1-prop-2-enylimidazolidine-2,4-dione supplier AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 1-prop-2-enylimidazolidine-2,4-dione vendor You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 1-prop-2-enylimidazolidine-2,4-dione factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.
